Incannex Healthcare Ltd
NASDAQ:IXHL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (14.7), the stock would be worth $-91.3 (2 429% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.6 | $3.92 |
0%
|
| Industry Average | 14.7 | $-91.3 |
-2 429%
|
| Country Average | 21 | $-130.6 |
-3 432%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Incannex Healthcare Ltd
NASDAQ:IXHL
|
43.3m USD | -0.6 | -2.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 154.7 | 43.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 29.4 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 35.4 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 24.6 | 14.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 44.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 22 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 11.9 | 17.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.2 |
| Median | 21 |
| 70th Percentile | 32.6 |
| Max | 583 153.2 |
Other Multiples
Incannex Healthcare Ltd
Glance View
Incannex Healthcare Ltd. is a cannabinoid and psychedelic compound medicine development company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-05-23. The company is a clinical stage pharmaceutical development company. The firm is engaged in developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. Its product candidate IHL-42X is developing a combination of acetazolamide and dronabinol to reduce the apnea hypopnea index (AHI), IHL-216A is a combination of isoflurane and CBD to prevent development of traumatic brain injury (TBI)/concussion, HL-675A comprises a combination of hydroxychloroquine and CBD in prevention and treatment of inflammatory lung conditions (ARDS, COPD, asthma, and bronchitis), rheumatoid arthritis and inflammatory bowel diseases and Psi-GAD is providing Psychedelic-assisted psychotherapy for Generalized Anxiety Disorder (GAD).
